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June 1, 2010:2514–7dmitted within 6 h of symptom onset. Further studies in larger
umbers of patients are needed to verify our results.
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2003;67:687–90.Letter to the Editorigh-Dose Statin,
ot So IDEAL?
ikkanen et al. (1) present an interesting post-hoc analysis of the
DEAL (Incremental Decrease in Endpoints Through Aggressive
ipid Lowering) study with a novel statistical method using all
ascular rather than just the first cardiovascular events recorded, and
hey propose highly significant p values in support of using top-dose
torvastatin (80 mg/day) versus “standard” dose simvastatin (20
g/day or uptitrated). The authors propose that such a statistical
pproach is of value because of the health economic importance of
ubsequent events, and that their results “suggest that clinicians should
ot hesitate to prescribe high-dose statin therapy for patients experi-
ncing multiple recurrent cardiovascular events.”
The background: The IDEAL study was an apparently well-
un, open-label drug comparison trial in all post-myocardial infarct
MI) patients, of whom about 40% had already experienced
evascularization and an 8.3% mortality rate (0.1% between
roups) during the mean 4.8 years of follow-up. The lack of
ortality benefit is in line with atorvastatin’s well-known inability
o lower mortality, with the notable findings of the TNT (Treating
o New Targets) trial and the SPARCL (Stroke Prevention by
ggressive Reduction in Cholesterol Levels) trial that ended with
umerically more deaths on top-dose atorvastatin than on low-
ose and placebo, respectively (2,3).
Since mortality is not reduced, we have to ask about the nature
f events prevented. The authors report that the first, second, and
hird events recorded were 46%, 51%, and 43% on the basis of
ecisions to hospitalize or to revascularize, whereas nonfatal MIsAnglo-Scandinavian Cardiac Outcomes Trial) study found angina
educed by 41%, likely by the nitric oxide/endothelial nitric oxide
ynthase nitroglycerin mimicking action that all statins share (4,5).
he amount of angina experienced is a factor potentially affecting
he medical decisions and the number of MIs recorded in a trial.
Thus, we have to be careful including these softer end points, and
ince the authors bring up health economics, we should be aware that
t the current (Vermont) retail prices of $5 per pill for “high
ose-statin” (Lipitor 80 mg and Crestor 20 mg), it would cost, as an
xample, from $560,000 to $1,160,000—slightly less in men, more in
omen—to prevent either a revascularization, stroke, or MI on the
asis of the results of the recent JUPITER (Justification for the Use of
tatins in Primary Prevention: An Intervention Trial Evaluating
osuvastatin) primary prevention study (rosuvastatin 20 mg vs.
lacebo) (6). Even at the current Vermont price for generic lovastatin
$0.78 for 20mg), such costs, likely even in secondary prevention, may
e many times those of an angioplasty, a hospitalization for angina, or
he cost of a (not clearly defined nor quantified by Tikkanen et al. [1])
eripheral vascular disease event.
These drug costs call into question the benefit of statins, including
igh-dose statin, regarding health economic benefits. Therefore,
ould the authors comment on the health economic effects of their
xpanded end point analysis, and provide numbers needed to treat for
ndividual end points, with confidence intervals?
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